Mechanism of Action Influences Sequencing of Systemic GVHD Therapies
Noah M. Merin, MD, PhD, discusses the mechanisms of action and sequencing of oral therapies for chronic graft-vs-host disease (GVHD) in a live virtual event.
Noah M. Merin, MD, PhD, discusses the mechanisms of action and sequencing of oral therapies for chronic graft-vs-host disease (GVHD) in a live virtual event.
A sBLA has been submitted to the FDA for subcutaneous daratumumab plus VRd in ASCT-ineligible or -deferred multiple myeloma.
Cancer care disparities exist for underrepresented groups due to limited access to healthcare, clinical trials, and cultural barriers, but solutions like telemedicine and improved communication…
Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding
An abstract is unavailable.
Neoadjuvant sotigalimab plus chemoradiotherapy is safe and feasible compared with chemoradiotherapy alone in patients with rectal cancer.
FDA Oncology Center of Excellence Presents: Conversations on Cancer: “Pazdur + 25—Celebrating a Silver FDA Anniversary”
Over a three-year study period ibrutinib use in the US decreased while acalabrutinib and zanubrutinib use increased.
Elias Jabbour, MD, discusses how advancements in the administration and sequencing of TKIs have improved long-term prognosis for patients with CML.
You Know I Know. The brand new album. OUT NOW: http://smarturl.it/ykikdlxYTDStream the album in full on Spotify here: http://smarturl.it/OMMusicPlaylist Kee…